Summary
Smoking is 2–3 times more prevalent and quitting is 2–3 times less prevalent in psychiatric patients than in the general population. Whether this is due to neurotransmitter or behavioral deficits, attempts to combat medication side-effects, modeling or adjunctive behavior is unknown. Studies of the association of smoking and schizophrenia illustrate how smoking may modulate symptoms of a disorder and interfere with the efficacy and acceptability of treatment of the disorder. Thus, psychiatric clinicians and researchers need to record and adjust for the smoking behavior of their patients/subjects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hughes JR.: Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment. J Clin Psychiatr 1993; 54: 109–114.
Glassman AH.: Cigarette smoking: Implications for psychiatric illness. Am J Psychiatr 1993; 150: 546–553.
Cigarette smoking among adults – United States, 1991. Morbidity and Mortality Weekly Report 1993.
Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren BA.: Prevalence of smoking in psychiatric outpatients. Am J Psychiatr 1986; 143: 993–997.
Kandel DB, Davies M.: Adult sequelae of adolescent depressive symptoms. Arch Gen Psychiatr 1986; 43: 255–262.
Lerner JV, Vicary JR.: Difficult temperament and drug use: Analyses from the New York longitudinal study. J Drug Education 1984; 14: 1–9.
Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves U, Kessler RC.: Smoking and major depression. Arch Gen Psychiatr 1993; 50: 36–43.
Hughes JR.: Clonidine, depression and smoking cessation. JAMA 1988; 254: 2901–2902.
Pomerleau OF, Pomerleau CF.: Neuroregulators and the reinforcement of smoking: Towards a biobehavioral explanation. Neuroscience and Biobehavioral Reviews 1984; 8: 503–513.
US Department of Health and Human Services. Effects of nicotine that may promote tobacco use. In: Benowitz NL, Grunberg NE, Henningfield JE, Lando HA, eds. The Health Consequences of Smoking. Nicotine Addiction, Washington, USDHHS, Pub No (CDC) 88–8406:A Report of the Surgeon General, 1988: 377–458.
Falk JL.: Schedule-induced drug self-administration. In: Van Haaren F, ed. Methods in Behavioral Pharmacology. Amsterdam: Elsevier Science Publishers, 1993: 301–328.
Lohr JB, Flynn K.: Smoking and schizophrenia. Schizophrenia Research 1992; 8: 93–102.
Davis KL, Kahn RS, Ko G, Davidson M.: Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatr 1991; 148: 1474–1486.
Clarke PBS.: Recent advances in understanding the actions of nicotine in the central nervous system. J Natl Cancer Inst Monograph 1992; 2: 229–238.
Ziedonis DM, Kosten TR, Glazer WM, Frances RJ.: Nicotine dependence and schizophrenia. Hosp Comm Psychiatr 1994; 45: 204–206.
Goff DC, Henderson DC, Amico E.: Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatr 1992; 149: 1189–1194.
Stimmel G, Falloon I.: Chlorpromazine plasma levels, adverse effects, and tobacco smoking: Case report. J Clin Psychiatr 1983; 44: 420–421.
Vinarova E, Vinar O, Kalvach Z.: Smokers need higher doses of neuroleptic drugs. Biol Psychiatr 1984; 19: 1265–1268.
Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA, Davis CM.: Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharm 1986; 90: 468–470.
Miller DD, Kelly MW, Perry PJ, Coryell WH.: The influence of cigarette smoking on haloperidol pharmacokinetics. Biol Psychiatr 1990; 28: 529–531.
Decina P, Caracci G, Sandik R, Berman W, Mukherjee S, Scapicchio P.: Cigarette smoking and neuroleptic-induced parkinsonism. Biol Psychiatr 1990; 28: 502–508.
Sandyk R, Kay SR.: Tobacco addiction as a marker of age at onset of schizophrenia. Intern J Neuroscience 1991; 57: 259–262.
Yassa R, Samarthji L, Korpassy A, Ally J.: Nicotine exposure and tardive dyskinesia. Biol Psychiatr 1987; 22: 67–72.
Menza MA, Grossman N, Van Horn M, Cody R, Forman N.: Smoking and movement disorders in psychiatric patients. Biol Psychiatr 1991; 30: 109–115.
Wagner B, Wolf GK, Ulmar G.: Does smoking reduce the risk of neuroleptic parkinsonoids? Pharmacopsychiatry 1988; 21: 302–303.
Yassa R, Lal S, Korpassy A, Ally J.: Nicotine exposure and tardive dyskinesia. Biol Psychiatr 1987; 22: 67–72.
Binder RL, Kazamatsure H, Nishimura T, McNiel DE.: Smoking and tardive dyskinesia. Biol Psychiatr 1987; 22: 1281–1282.
Youssef HA, Waddinton JL.: Morbidity and mortality in tardive dyskinesia: Associations in chronic schizophrenia. Acta Psychiatr Scand 1987; 75: 74–77.
Chiles JA, Cohen S, Maiuro R, Wright R.: Smoking and schizophrenic psychopathology. The American Journal on Addictions 1993; 2: 315–319.
Kirch DG, Alho AM, Wyatt R.I.: Hypothesis: A nicotine-dopamine interaction linking smoking with parkinson’s disease and tardive dyskinesia. Cellular and Molecular Neurobiology 1988; 8: 285–291.
Hughes JR, Howard TS.: Nicotine don’t get no respect. JAMA 1994; 271: 585.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Birkhäuser Verlag Basel
About this chapter
Cite this chapter
Hughes, J.R., McHugh, P. (1995). Nicotine and Neuropsychiatric Disorders: Schizophrenia. In: Clarke, P.B.S., Quik, M., Adlkofer, F., Thurau, K. (eds) Effects of Nicotine on Biological Systems II. Advances in Pharmacological Sciences. Birkhäuser Basel. https://doi.org/10.1007/978-3-0348-7445-8_39
Download citation
DOI: https://doi.org/10.1007/978-3-0348-7445-8_39
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-0348-7447-2
Online ISBN: 978-3-0348-7445-8
eBook Packages: Springer Book Archive